Literature DB >> 15960769

One of these things is not like the others: the idea of precedence in health technology assessment and coverage decisions.

Mita Giacomini1.   

Abstract

Health plans often deliberate covering technologies with challenging purposes, effects, or costs. They must integrate quantitative evidence (e.g., how well a technology works) with qualitative, normative assessments (e.g., whether it works well enough for a worthwhile purpose). Arguments from analogy and precedent help integrate these criteria and establish standards for their policy application. Examples of arguments are described for three technologies (ICSI, genetic tests, and Viagra). Drawing lessons from law, ethics, philosophy, and the social sciences, a framework is developed for case-based evaluation of new technologies. The decision-making cycle includes (1) taking stock of past decisions and formulating precedents, (2) deciding new cases, and (3) assimilating decisions into the case history and evaluation framework. Each stage requires distinctive decision maker roles, information, and methods.

Entities:  

Keywords:  Health Care and Public Health

Mesh:

Year:  2005        PMID: 15960769      PMCID: PMC2690141          DOI: 10.1111/j.1468-0009.2005.00344.x

Source DB:  PubMed          Journal:  Milbank Q        ISSN: 0887-378X            Impact factor:   4.911


  27 in total

1.  Priority setting in health policy in Sweden and a comparison with Norway.

Authors:  J Calltorp
Journal:  Health Policy       Date:  1999-12       Impact factor: 2.980

2.  Reducing normative bias in health technology assessment: interactive evaluation and casuistry.

Authors:  R P Reuzel; G J van der Wilt; H A ten Have; P F de Vries Robbé
Journal:  Med Health Care Philos       Date:  1999

Review 3.  Willingness to pay for a quality-adjusted life year: in search of a standard.

Authors:  R A Hirth; M E Chernew; E Miller; A M Fendrick; W G Weissert
Journal:  Med Decis Making       Date:  2000 Jul-Sep       Impact factor: 2.583

4.  Interactive technology assessment and wide reflective equilibrium.

Authors:  R P Reuzel; G J van der Wilt ; H A ten Have; P F de Vries Robbé
Journal:  J Med Philos       Date:  2001-06

5.  Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers.

Authors:  Norman Daniels; James Sabin
Journal:  Philos Public Aff       Date:  1997

6.  Casuistry: an alternative or complement to principles?

Authors:  Albert R Jonsen
Journal:  Kennedy Inst Ethics J       Date:  1995-09

Review 7.  The economics of Viagra.

Authors:  A Keith
Journal:  Health Aff (Millwood)       Date:  2000 Mar-Apr       Impact factor: 6.301

8.  Cost utility analysis of sildenafil compared with papaverine-phentolamine injections.

Authors:  E A Stolk; J J Busschbach; M Caffa; E J Meuleman; F F Rutten
Journal:  BMJ       Date:  2000-04-29

9.  The cost-effectiveness of sildenafil.

Authors:  K J Smith; M S Roberts
Journal:  Ann Intern Med       Date:  2000-06-20       Impact factor: 25.391

10.  Screening for factor V Leiden mutation before prescribing combination oral contraceptives.

Authors:  M D Creinin; R Lisman; R C Strickler
Journal:  Fertil Steril       Date:  1999-10       Impact factor: 7.329

View more
  11 in total

1.  The force of dissimilar analogies in bioethics.

Authors:  Heidi Mertes; Guido Pennings
Journal:  Theor Med Bioeth       Date:  2011-04

2.  How good is good enough? Standards in policy decisions to cover new health technologies.

Authors:  Mita Giacomini
Journal:  Healthc Policy       Date:  2007-11

3.  Analysing coverage decision-making: opening Pandora's box?

Authors:  Katharina Elisabeth Fischer; Reiner Leidl
Journal:  Eur J Health Econ       Date:  2014-02-06

4.  6-STEPPPs: A Modular Tool to Facilitate Clinician Participation in Fair Decisions for Funding New Cancer Drugs.

Authors:  George P Browman; Braden Manns; Neil Hagen; Carole R Chambers; Anita Simon; Shane Sinclair
Journal:  J Oncol Pract       Date:  2008-01       Impact factor: 3.840

5.  Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.

Authors:  Mireille M Goetghebeur; Monika Wagner; Hanane Khoury; Donna Rindress; Jean-Pierre Grégoire; Cheri Deal
Journal:  Cost Eff Resour Alloc       Date:  2010-04-08

6.  Ethical analysis to improve decision-making on health technologies.

Authors:  Samuli I Saarni; Bjørn Hofmann; Kristian Lampe; Dagmar Lühmann; Marjukka Mäkelä; Marcial Velasco-Garrido; Ilona Autti-Rämö
Journal:  Bull World Health Organ       Date:  2008-08       Impact factor: 9.408

7.  Understanding relevance of health research: considerations in the context of research impact assessment.

Authors:  Mark J Dobrow; Fiona A Miller; Cy Frank; Adalsteinn D Brown
Journal:  Health Res Policy Syst       Date:  2017-04-17

8.  Technology assessment and resource allocation for predictive genetic testing: a study of the perspectives of Canadian genetic health care providers.

Authors:  Alethea Adair; Robyn Hyde-Lay; Edna Einsiedel; Timothy Caulfield
Journal:  BMC Med Ethics       Date:  2009-06-18       Impact factor: 2.652

9.  Why not integrate ethics in HTA: identification and assessment of the reasons.

Authors:  Bjørn Hofmann
Journal:  GMS Health Technol Assess       Date:  2014-11-26

10.  Steps toward improving ethical evaluation in health technology assessment: a proposed framework.

Authors:  Nazila Assasi; Jean-Eric Tarride; Daria O'Reilly; Lisa Schwartz
Journal:  BMC Med Ethics       Date:  2016-06-06       Impact factor: 2.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.